CLIC-2201 for relapsed or refractory B cell cancers
Part of Blood & lymphatic, Cancer, Immune system & allergy, Infections clinical trials.
This trial tests a new treatment called CLIC-2201 for people with certain types of B cell lymphoma or leukemia that have come back or not responded to previous treatments. It aims to see if this therapy can help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older (for the adult group) or between 1 and 39 years old (for the pediatric/young adult group).
- You must have a type of B cell lymphoma or B cell acute lymphoblastic leukemia that has returned or not responded to at least 2 prior treatments, or has returned after a stem cell transplant or CAR-T therapy.
- Your heart, kidneys, and liver must be working well enough, as checked by tests.
- You must be able to care for yourself (performance status of 0-2 on the ECOG scale or a Karnofsky/Lansky score of at least 50%).
- You must agree to use effective birth control for at least one year after treatment if you are of reproductive age.
- You must be willing to have a tumor or bone marrow biopsy before starting the trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies a gene-modified cell treatment called CLIC-1901 for people whose CD19-positive cancer has come back or did not respond to prior treatment. It may help shrink the cancer by targeting a protein called CD19 on cancer cells.
This Phase 1/2 trial tests CRC01, a lab-made immune cell therapy, for adults whose lymphoma or B-cell leukemia has come back or did not respond to treatment. If you qualify, the study aims to see how safe CRC01 is and whether it can shrink tumors and improve outcomes.
This trial tests a new type of immune cell therapy (CAR-T cells) that targets a protein called CD19 on your lymphoma cells. It's for people whose B-cell lymphoma has returned or not responded to standard treatments.
This trial tests a new treatment called GI001 for people with B-cell lymphoma or B-cell leukemia that has come back or hasn't responded to previous treatments. It aims to see if GI001 can help when other options have failed, and it may be an option if you haven't had CAR-T therapy before.
This trial tests a new kind of immune cell therapy for people with certain types of lymphoma that have come back or not responded to previous treatments. The cells are made from your own blood and are designed to find and attack the cancer cells.
This trial tests whether the experimental drug TC011 can help adults with a type of B-cell lymphoma that has come back or stopped responding after at least two rounds of chemotherapy. The study checks for safety and whether the treatment can shrink tumors.
Hear when a new Leukemia, B-cell trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.